Litigation Details for HZNP Finance Limited v. Actavis Laboratories UT, Inc. (Fed. Cir. 2017)
✉ Email this page to a colleague
HZNP Finance Limited v. Actavis Laboratories UT, Inc. (Fed. Cir. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-06-13 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | 2019-10-10 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Parties | HZNP FINANCE LIMITED | ||
| Patents | 6,387,383; 8,217,078; 8,252,838; 8,546,450; 8,563,613; 8,618,164; 8,741,956; 8,871,809; 9,061,064; 9,066,913; 9,101,591; 9,132,110; 9,168,304; 9,168,305; 9,220,784; 9,339,551; 9,339,552; 9,370,501; 9,375,412; 9,539,335 | ||
| Attorneys | Caryn Borg-Breen | ||
| Firms | Direct: 202-772-8854, Sterne Kessler Goldstein & Fox, PLLC, Firm: 202-772-8825 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in HZNP Finance Limited v. Actavis Laboratories UT, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in HZNP Finance Limited v. Actavis Laboratories UT, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for HZNP Finance Limited v. Actavis Laboratories UT, Inc. (Fed. Cir. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-08-16 | 33 | Patent No. 8,217,078 the ’110 patent United States Patent No. 9,132,110 the ’838 patent … ’591 patent”), 8,546,450 (“the ’450 patent”), 8,217,078 (“the ’078 patent”), 8,618,164 (“the ’164…the ’450 patent”), 8,217,078 (“the ’078 patent”), 8,618,164 (“the ’164 patent”) and 9,132,110 (“the …. United States Patent No. 8,217,078…………….……………..…..A65-A119 7. United States Patent No. 8,252,838…………U.S. Patent Nos. 8,546,450; 8,217,078; 8,618,164; and 9,132,110 - are part of the “’450 Patent Family | External link to document | |
| 2017-08-16 | 36 | This patent is subject to a renninal dis- 6,387,383 Bl 512002 Dow… 6,387,383 Bl 5/2002 Dow el al. … 6,387,383 Ill 5/2002 Dow el al, …’110 patent the ’838 patent family the ’838 patent, the ’613 patent, the ’809 patent, the … of the ’078 patent, the ’838 patent, the ’450 patent, the ’613 patent, the ’164 patent, and the ’809 | External link to document | |
| 2017-10-10 | 41 | various ingredients in a composition.” Appx139 (9:61-64). Accordingly, the amount of “impurities…See Appx121 (’838 patent Abstract); Appx152 (’450 patent Abstract).1 These patents are listed in the …’838 patent (the formulation patents), except where otherwise indicated. The formulation patents include…Horizon owns U.S. Patent No. 9,066,913 (“the ’913 patent”), which is among the patents listed in the Orange…Pharma USA, Inc.) U.S. Patent No. 9,066,913 (the “‘913 patent”). The ‘913 patent concerns PENNSAID® | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
